DK3820439T3 - Mukoadhæsivt dispersionsnanopartikelsystem og fremgangsmåde til fremstilling deraf - Google Patents

Mukoadhæsivt dispersionsnanopartikelsystem og fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number
DK3820439T3
DK3820439T3 DK18786389.9T DK18786389T DK3820439T3 DK 3820439 T3 DK3820439 T3 DK 3820439T3 DK 18786389 T DK18786389 T DK 18786389T DK 3820439 T3 DK3820439 T3 DK 3820439T3
Authority
DK
Denmark
Prior art keywords
manufacture
adhesive dispersion
nanoparticle system
dispersion nanoparticle
muco adhesive
Prior art date
Application number
DK18786389.9T
Other languages
English (en)
Inventor
Christo Tzachev Tzachev
Original Assignee
Lead Biotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Biotherapeutics Ltd filed Critical Lead Biotherapeutics Ltd
Application granted granted Critical
Publication of DK3820439T3 publication Critical patent/DK3820439T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
DK18786389.9T 2018-09-11 2018-09-11 Mukoadhæsivt dispersionsnanopartikelsystem og fremgangsmåde til fremstilling deraf DK3820439T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2018/001073 WO2020053609A1 (en) 2018-09-11 2018-09-11 Mucoadhesive dispersion nanoparticle system and method for production the same

Publications (1)

Publication Number Publication Date
DK3820439T3 true DK3820439T3 (da) 2021-12-20

Family

ID=63857975

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18786389.9T DK3820439T3 (da) 2018-09-11 2018-09-11 Mukoadhæsivt dispersionsnanopartikelsystem og fremgangsmåde til fremstilling deraf

Country Status (14)

Country Link
US (1) US12036329B2 (da)
EP (1) EP3820439B1 (da)
JP (1) JP7164700B2 (da)
CA (1) CA3110773C (da)
DK (1) DK3820439T3 (da)
ES (1) ES2901469T3 (da)
HR (1) HRP20211996T1 (da)
HU (1) HUE056959T2 (da)
IL (1) IL280371B (da)
LT (1) LT3820439T (da)
MX (1) MX2021001397A (da)
PL (1) PL3820439T3 (da)
SI (1) SI3820439T1 (da)
WO (1) WO2020053609A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019116062A1 (en) * 2017-12-12 2019-06-20 Lead Biotherapeutics Ltd. Solid lipid nanoparticle for intracellular release of active substances and method for production the same
CN120788994B (zh) * 2025-09-12 2025-11-14 广东海洋大学 一种具有增溶和促吸收作用的纳米复合物及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603131A (en) 1982-04-26 1986-07-29 Bernstein Joel E Method and composition for treating and preventing irritation of the mucous membranes of the nose
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
CA2311530C (en) 1998-01-30 2008-06-10 Novartis Consumer Health S.A. Nasal solutions
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
GB2423711B (en) 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
ES2284398B2 (es) 2006-04-27 2008-12-16 Universidad Complutense De Madrid Formulacion de vesiculas liposomales en soluciones acuosas con caracteristicas de pelicula lagrimal.
US8242165B2 (en) 2006-10-26 2012-08-14 Creighton University Mucoadhesive nanoparticles for cancer treatment
EP2123261A1 (en) 2008-05-20 2009-11-25 Stallergenes S.A. Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
WO2012017449A1 (en) * 2010-08-04 2012-02-09 Meril Life Sciences Pvt. Ltd Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
EP2688560A2 (en) * 2011-03-24 2014-01-29 Leo Pharma A/S A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative
US9993439B2 (en) 2012-06-20 2018-06-12 University Of Waterloo Mucoadhesive nanoparticle delivery system
EP3010489A1 (en) * 2013-06-20 2016-04-27 Glenmark Pharmaceuticals S.A. Nanoparticulate formulation comprising a trpa1 antagonist
CN103784421B (zh) * 2014-02-27 2016-04-27 哈尔滨医科大学 载姜黄素和胡椒碱的固体脂质纳米粒及其制备方法
AU2015277272A1 (en) * 2014-06-16 2017-01-12 Loewi LLC Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof
JP2016034918A (ja) * 2014-08-01 2016-03-17 静岡県公立大学法人 難水溶性抗酸化物質送達用組成物
EP3368008A1 (en) 2015-10-30 2018-09-05 The Johns Hopkins University Mucus penetrating particles with high molecular weight and dense coatings
WO2017097783A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Biologicals S.A. Novel adjuvant formulations

Also Published As

Publication number Publication date
HRP20211996T1 (hr) 2022-04-01
BR112021001674A2 (pt) 2021-05-04
MX2021001397A (es) 2021-04-12
IL280371A (en) 2021-03-01
ES2901469T3 (es) 2022-03-22
US12036329B2 (en) 2024-07-16
PL3820439T3 (pl) 2022-04-04
JP7164700B2 (ja) 2022-11-01
HUE056959T2 (hu) 2022-04-28
EP3820439B1 (en) 2021-09-29
CA3110773A1 (en) 2020-03-19
SI3820439T1 (sl) 2022-02-28
LT3820439T (lt) 2022-01-10
US20210353553A1 (en) 2021-11-18
IL280371B (en) 2021-05-31
CA3110773C (en) 2023-02-28
WO2020053609A1 (en) 2020-03-19
EP3820439A1 (en) 2021-05-19
JP2022511223A (ja) 2022-01-31

Similar Documents

Publication Publication Date Title
DK3601358T5 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
EP3784322C0 (en) Catheterization system and methods for use thereof
DK3411151T3 (da) Mikrofluidt assaysystem og fremgangsmåde til at udføre et assay
DK3727130T3 (da) Medicinsk system og fremgangsmåde til fremstilling deraf
DK3618928T3 (da) Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3478441T3 (da) Væskesystem og fremgangsmåde til fremstilling via friktionssvejsning
DK3447137T3 (da) Flydende enzympræparat og fremgangsmåde til fremstilling deraf
DK3525583T3 (da) Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3320457T3 (da) System og fremgangsmåde til elektronisk datadistribution
DK3275334T3 (da) Gelnegleklistermærke og fremgangsmåde til fremstilling deraf
EP3603853A4 (en) MODELING SYSTEM AND MODELING PROCESS
DK3743447T3 (da) B7-H4-antistoffer og fremgangsmåder til anvendelse deraf
DK3250610T3 (da) Fcrn-antistoffer og fremgangsmåder til anvendelse heraf
PL3474996T3 (pl) Urządzenie zamgławiające i sposób zastosowania
DK3491025T3 (da) Fcrn-antistoffer og anvendelsesmetoder heraf
DK3727807T3 (da) Modulopbygget vindmøllevinge og fremgangsmåde til fremstilling deraf
DK3390442T3 (da) Anti-C5 antistoffer og fremgangsmåde til anvendelse deraf
DK3555391T3 (da) Bærbart multifunktionelt system og fremgangsmåde til fremstilling heraf
DK3368578T3 (da) Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf
DK3231405T3 (da) Fremgangsmåde til at forudsige udskillelser og indretning hertil
DK3332940T3 (da) Silikoneekstruderingsanlæg og fremgangsmåde til silikoneekstrudering
DK3577909T3 (da) Fremgangsmåde til at betjene et høreapparatsystem og et høreapparatsystem
DK3618883T3 (da) Smøredygtige hydrofile belægninger og fremgangsmåder til dannelse heraf
GB2580264B (en) Optical modulator and method of fabricating an optical modulator